Companie

Lupin launches generic inhalation product in US market

PTI New Delhi | Updated on June 04, 2021

The drug is to be used by nebulisation only

Drug firm Lupin on Friday said it has launched Arformoterol Tartrate, an inhalation product to treat conditions like chronic bronchitis and emphysema, in the US market.

The Mumbai-based company's product is the generic version of Sunovion Pharmaceuticals Inc's Brovana inhalation solution, Lupin said in a statement.

Arformoterol Tartrate inhalation solution is indicated for the long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

It is for use by nebulisation only, the drugmaker noted.

Shares of Lupin were trading 0.39 per cent up at ₹1,237.20 apiece on the BSE.

Published on June 04, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Lupin Ltd
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.